The Effect of High-Dose Vitamin D3 on 28-Day Mortality in Adult Critically III Patients with Severe Vitamin D Deficiency The UK Arm of a Multi-Centre, Placebo-Controlled Double-Blind Phase III Randomised Controlled Trial



VIT<u>D</u>ALIZE UK

PATIENT INFORMATION SHEET

We would like to invite you to take part in our research trial

You are being asked to consider taking part in a research trial. Before you decide, we would like you to understand why the research is being done and what it would involve for you. A member of our team will go through this information sheet with you and answer any questions. You can talk to others about this if you wish and please ask us if there is anything that is not clear.

What is the purpose of the trial?

The aim of this research trial is to see if giving high dose of vitamin D in critically ill patients can improve survival, length of hospital stay, and quality of life.

Vitamin D deficiency (low vitamin D levels) is common (around 70%) in patients who are unwell. This has been found to be related to an increased risk of infection and death. There are many reasons why patients are poorly and those who do survive can suffer long-term health problems in the future.

It is not known whether being vitamin D deficient is a cause or effect of being unwell, and research into whether vitamin D is useful is not clear. The reason we are doing this trial is because there are no guidelines to measure and treat patients admitted to intensive care who are critically ill and are vitamin D deficient. Vitamin D is cheap, and easily available, and if using vitamin D is found to help, can be quickly put into standard practice in hospitals.

Why have I been invited? Can I say no?

You have been invited to be a part of this trial because you are expected to be in intensive care for more than 2 days, are critically ill and may have vitamin D deficiency.

VITDALIZE is an international trial that aims to recruit 2400 patients from across Europe. Countries that are participating includes the UK, Austria, Germany and Belgium. The UK part of VITDALIZE aims to recruit 600 patients into the trial.

It is up to you to decide whether to take part. If you do decide to take part, you will be given this information sheet to keep and be asked to sign a consent form. This will stay on record in your trial file, be noted in your medical records, and be available for review by the research team, representatives of the Sponsor, regulatory authorities, or from the NHS Trust, where relevant to your participation in this research trial. A copy will also be held at Birmingham Clinical Trials Unit, University of Birmingham and one will be made for you to keep. If you decide not to take part, your normal treatment will not be affected in any way and you will continue to be cared for as you would normally.

Are there any benefits to taking part?

Although there may be no direct benefits to you taking part in this trial, the results of the trial will lead to the best treatment being offered to patients who are unwell and are vitamin D deficient.

What will happen to me if I take part and how do I receive the medication?

Sometimes we do not know which way of treating patients is best. To find out, we need to compare different treatments by putting patients into groups with each receiving a different treatment. To make the groups fair, each patient will be put into a group by chance (randomly). You will receive either a high dose of vitamin D or a placebo (dummy drug); this would be given orally or by your feeding tube. You will then receive a daily dose of either vitamin D or placebo for up to 90 days which you will take orally (by mouth),or be given through your existing feeding tube. If you are discharged during this time, you will be given the remaining doses to take at home. You should take the trial medication regularly as directed and continue to take all of your other regular medication too.

The VITDALIZE UK Trial is a blinded trial; this means that no one will know what you have received. With your consent, the research team will inform you of what you have received once the trial has been completed.

Screening

If you think you might be interested in taking part in the VITDALIZE UK Trial, you will first need to be screened to see if you are eligible to take part. This means the research team will need check if you have severe vitamin D deficiency.

If you decide to be screened for inclusion in the VITDALIZE UK Trial the research team will:

- Review your medical history
- Take a blood sample (approximately 5-10 ml, equivalent to 2 teaspoons) to measure vitamin D level

If a blood sample has already been taken as part of your usual care today, you may not need to have another one. This will be discussed with you at the time.

Once the results of the screening tests are available, the research team will tell you whether you are able to participate in the VITDALIZE UK Trial.

What happens if the results show that I am not able to take part?

If the results show that you are not able to participate in the VITDALIZE UK Trial, the research team will let you know as soon as practically possible and explain that your care will continue as part of routine practice.

What happens if the results show that I am able to take part?

If the results show that you are able to take part in the VITDALIZE UK Trial, the research team will randomise you into the trial. You will be informed as soon as practically possible, after this has taken place.

What will happen to me if I take part in the main VITDALIZE UK Trial?

How many visits are there and how long will it take?

For the VITDALIZE UK Trial, the research team will visit or contact you up to 6 times (days 0, 5, 12, 28, 90 and 1 year), after your randomisation into the trial. If you are still in hospital, the information will be gathered from your medical records.


At the beginning of the trial, you will be given either a high dose of vitamin D or placebo (day 0). You will then begin taking a daily dose of either vitamin D or placebo from day 1 to day 90.

On day 5 (if you are still in hospital), the research team will take some more blood (10-20 ml, the equivalent to one tablespoon), this is to see how they are responding to treatment. Where possible, this will be taken while you have your standard blood tests. On rare occasions that this cannot be done, we will ask if you are willing to have another blood test.

On days 0, 28, 90 and 1 year the research team will contact you (either in person if you are still in hospital or via telephone), and ask you a few questions about your health. This should take no longer than 20 minutes.

As part of the VITDALIZE UK Trial, you will be asked for your consent to provide optional blood samples at up to 3 additional time points. This would be for future approved research assessing the effects of vitamin D treatment on vitamin D pathway and markers of immune function. This would mean providing blood samples (25-30 ml; equivalent to 2 tablespoons) on days 0, 5 and 12. The samples will be collected by the research team and initially stored at the hospital, they will then be transported to the University of Birmingham for storage and analysis by the Chief Investigator. More information relating to what happens to your samples can be found below in 'what will happen to any samples I give?' If you would prefer not to provide these blood samples, it will not affect their participation in VITDALIZE UK.

Trial assessment flow chart



There may be some situations, during your participation in the trial where you need to be taken to another hospital to receive specific treatment for your condition. If this happens, with your consent, we would contact the hospital where you are receiving treatment and ask them to provide some information about how you are getting on. Doing so would help us better answer the research question, but it is optional and you can say no at any time.

Are the treatments and tests safe?

High dose vitamin D can have some side effects, those reported include:

• Increased level of calcium in the blood and urine

• Digestive issues such as constipation, flatulence, nausea, stomach-ache and diarrhoea

We will carefully monitor any side effects and there will be an independent safety committee that will oversee the trial to make sure that it is safe to continue taking the trial medication.

What happens when the research trial stops?

After the trial has finished, your clinical care will revert to the current standard care for patients who have severe vitamin D deficiency. The research team will inform your GP that you had severe vitamin D deficiency and were randomised into the VITDALIZE UK Trial.

What if new information becomes available?

Sometimes we get new information about the treatments being studied. If this happens, your research doctor will tell you and discuss whether you should continue in the trial. If the trial is stopped for any other reason, we will tell you and arrange your continuing care.

What will happen if I do not want to carry on?

You can withdraw from the trial at any time without giving a reason. If you do decide to withdraw from the trial, the information collected until your withdrawal may still be used as part of the trial analysis.

What if there is a problem?

If you have a concern about any aspect of this trial, you should ask to speak to the researchers who will do their best to answer your questions (see contact details on the **last page**). If you remain unhappy and wish to complain formally, in England and Wales you can do this by contacting the Patient Advice and Liaison Services (PALS), in Scotland you contact the Patient Advice and Support Service (PASS) and Northern Ireland Patient and Client Council.

Contact details are: << INSERT LOCAL DETAILS HERE>>.

Insurance and indemnity arrangements for VITDALIZE UK

On behalf of the Sponsor, The Medical University of Graz, Austria, The University of Birmingham will act as the National Coordinating Centre (NCC) and will oversee the management of the VITDALIZE Trial in the UK. In the unlikely event that something does go wrong and you are harmed during the research due to someone's negligence, then you may have grounds for legal action and compensation against The University of Birmingham but you may have to pay your legal costs. The normal NHS complaints mechanisms will still be available to you if appropriate.

The University of Birmingham has taken out clinical trial insurance for participants in the UK for the duration of the trial. The insurance will cover legal liability or no fault insurance to assist you if a claim is made.

The Sponsor is responsible for obtaining general liability insurance cover for any claims against them.

Will my details be kept confidential?

Health and care research should serve the public interest which means that we have to demonstrate that the research serves the benefits of society as a whole. We do this by

adhering to the regulations that govern clinical trials in the UK.

All information collected about you for this trial will be subject to the General Data Protection Regulation (GDPR) and Data Protection Act 2018 for health and care research and will be kept strictly confidential. Data collected in the UK for the VITDALIZE UK Trial by the NCC or UK hospitals is the exclusive property of the NCC. The NCC will be using information from your medical records in order to undertake this trial and will act as the data processor and data controller. This means that the NCC are responsible for looking after your information and using it properly. The NCC and the NHS will keep identifiable information about you for at least 25 years after the trial has finished to allow the results of the trial to be verified if needed.

All information collected by the NCC will be securely stored in the VITDALIZE UK Trial Office at the University of Birmingham on paper and electronically, and will only be accessible by authorised personnel. The only people in the University of Birmingham who will have access to information that identifies you will be people who manage the trial or audit the data collection process. There is an open-access VITDALIZE UK Trial website www.birmingham.ac.uk/vitdalizeuk that contains information about the trial. No identifiable information about you will be available on this website.

The NHS will use your name and contact details to contact you about the research trial and make sure that relevant information about the trial is recorded for your care, and to oversee the quality of the trial. With your permission, a copy of your signed consent form will also be sent to the University of Birmingham as the NCC in the UK for this trial.

At the VITDALIZE UK Trial Office, you will be identified by a unique trial number. In routine communication between your hospital and the VITDALIZE UK Trial Office, you will be identified by trial number, initials and date of birth. Data may be provided to the VITDALIZE UK Trial Office on paper or electronically.

By taking part in the trial, you will be agreeing to allow research staff from the VITDALIZE UK Trial Office to look at the trial records, including your medical records. It may be necessary to allow authorised personnel from government regulatory agencies (e.g. Medicines and Healthcare Products Regulatory Agency (MHRA), the Sponsor, the NCC and/or NHS bodies to have access to your medical and research records. This is to ensure that the trial is being conducted to the highest possible standards.

The data collected for all participants in the VITDALIZE UK Trial will be used by the Sponsor (Medical University of Graz) and international collaborators in the European Union (EU) in compliance with the current data transfer regulations. The data transferred will be pseudo-anonymised and comprise your trial number, age and sex.

From time to time, we may be asked to share the trial information (data) we have collected with researchers running other studies in this organisation and in other organisations so that they can perform analysis on the data to answer other important questions about critical illness and vitamin D deficiency. These organisations may be universities, NHS organisations or companies involved in health research and may be in this country or abroad. Any such request is carefully considered by the trial researchers and will only be granted if the necessary procedures and approvals are in place. This information will not identify you and will not be combined with other information in a way that could identify you. The information will only be used for the purpose of health research and cannot be used to contact you or to affect your care. It will not be used to make decisions about future services

available to you, such as insurance. Under no circumstances will you be identified in any way in any report, presentation or publication arising from this or any other trial.

To allow accurate follow up of all participants it will be necessary for the VITDALIZE UK Trial Office to contact other UK NHS bodies to provide information about your health. This would mean that the VITDALIZE UK Trial Office would use some of your personal identifiers (date of birth, NHS number (CHI number for patients in Scotland, H&C numbers for patients in Northern Ireland), trial number, age and sex. Your information will be held and maintained by central UK NHS bodies such as NHS digital.

All individuals who have access to your information have a duty of confidentiality to you.

Your rights to access change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. To safeguard your rights, we will use the minimum personally identifiable information possible. Under the provisions of the GDPR 2018, you have the right to know what information the VITDALIZE UK Trial Office has recorded about you. If you wish to view this information or find more about how we use this information, please contact Legal Services at the address below. Please note that a small fee may be payable to retrieve this information.

Legal Services University of Birmingham Edgbaston Birmingham, B15 2TT

Involvement of your family doctor?

Your GP will be kept informed of your participation in the trial. By consenting to take part, you agree to us sharing your progress in the trial with your GP, as needed for your clinical care.

What will happen to any samples I give?

If you decide to take part in the trial, we will take a blood sample to see if you have vitamin D deficiency (hospitals do not currently screen for this in the UK). These samples will be used and tested at the hospital and once the test is complete, the sample will be disposed of.

If you agree to having additional blood tests taken, the research team will take further blood samples at up to 3 additional time points. These will firstly be stored at the hospital where you are being treated and will then be transferred to the University of Birmingham for analysis and storage by the Chief Investigator of the VITDALIZE UK Trial. The samples will be pseudo-anonymised labelled using your trial number, date, and time point (e.g. visit 1) upon arrival at the University of Birmingham. The results may be shared with collaborators involved in the VITDALIZE UK Trial at the end of the trial in a pseudo-anonymised way (trial number, date and time point). Once the samples have been analysed the samples will be disposed of.

What will happen to the results of the research?

At the end of the trial, we will report results to the funder of the research and publish them in appropriate academic and professional journals and at conferences. We will contact you with the results of the trial once it is finished. The publications are made available to the general public on websites such as the NIHR, ClinicalTrials.gov, ICU networks, INVOLVE Clinical Research Ambassador Group, PubMed, open access Medical Education (FOAMed), charities such as the Intensive Care Unit Support Teams for Ex-Patients (ICUsteps) and the Critical Care Patients and Relatives Committee (PatRel), should you be interested. There

will also a Patient and Public Involvement (PPI) dissemination event to discuss the findings. You will not be identified in any publication.

Who is organising and funding the research?

VITDALIZE UK is funded by the National Institute for Health Research Health Technology Assessment Programme (Project Number: 17/147/33). It is sponsored by the Medical University of Graz, Austria and is being organised and run on their behalf by the Birmingham Clinical Trials Unit, located at the University of Birmingham in the UK.

No member of the research team are being paid for including you in this trial.

Who has reviewed the trial?

All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee, to protect your interests. This trial has been reviewed and given favourable opinion by South Central – Oxford C Research Ethics Committee.

Key points about this research:

Thank you for taking the time to read this information leaflet and for considering taking part in this research trial.

If you have any questions, please contact the trial research nurse on

<INSERT CONTACT DETAILS HERE>

Alternatively, you can contact the Chief Investigator for the research trial:

< INSERT CONTACT DETAILS HERE>